There has been significant investment in the development of neurodegenerative disease biomarkers—with innovations in AD research as an example—that include fluid biomarkers measured in cerebral spinal fluid (CSF) and the discovery of PET ligands that enable the determination of both amyloid beta and tau protein pathologies. This evidence concerns the gene MAPT and Alzheimer disease.